Impaired dopamine release in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlying the motor deficits in Parkinson’s disease. However, decades of research suggest that dopamine release deficits in Parkinson’s disease do not occur only after cell death, but that there is dysfunction or dysregulation of axonal dopamine release before cell loss. Here we review the evidence for dopamine release deficits prior to neurodegeneration in Parkinson’s disease, drawn from a large and emerging range of Parkinson’s disease models, and the mechanisms by which these release deficits occur. The evidence indicates that impaired dopamine release can result from disruption to a diverse range of Parkinson’s disease-associated genetic and molecular disturbances, and can be considered as a potential pathophysiological hallmark of Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This lack of dopamine is understood to be the primary cause of many of the movement disorders [127,128].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 2×
“Loss-of-function mutations in parkin are the most common cause of autosomal recessive Parkinson’s.95 Parkin, encoded by the PRKN gene (previously known as PARK2), is an E3 ubiquitin ligase that regulates proteasome-dependent protein degradation and plays a critical role in mitochondrial quality control.”
BackgroundAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 1×
“PINK1 is a mitochondrial protein kinase in which loss-of-function mutations are the second most frequent known cause of autosomal recessive Parkinson’s disease.(96) This protein regulates the activity of parkin, affects mitochondrial stability and modulates mito-”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563 · cited 1×
“Models employing SNpc or intrastriatal PFF injections that take advantage of the connectivity to the SNpc have the advantages that they have been shown to aggregate endogenous α-synuclein, induce progressive DA system neurodegeneration specific to SNpc while sparing the ventral tegmental area and recapitulate Parkinso…”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010) · Science · doi:10.1126/science.1195227 · Cited by 1,812
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765 · cited 2×
“TH, the rate-limiting enzyme in DA synthesis, has been shown to have decreased protein levels or decreased activity in models of Parkinson’s disease carrying mutations in LRRK2, SNCA, DJ-1 and PINK1.”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors
Patriarchi, T., Cho, J. R., Merten, K., Howe, M. W., Marley, A., Xiong, W.-H., Folk, R. W., Broussard, G. J., Liang, R., Jang, M. J., et al. (2018) · Science · doi:10.1126/science.aat4422 · Cited by 1,074
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 2×
“Dopaminergic axons are affected early in Parkinson’s disease, with synaptic decay preceding neuron death.(18,19) This concept is not unique to Parkinson’s disease; impaired synaptic activity and function, referred to as synaptopathy, is observed in a wide variety of neurodegenerative diseases, including Huntington’s,…”
BackgroundParkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308947200 · Cited by 913 · cited 3×
“Despite this, some reports observed motor phenotypes in the absence of cell death in Parkinson’s disease animal models.(38,40,58,61,66,143) This finding presents a critical challenge to the definition of Parkinson’s disease.”
BackgroundResultMitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration
Sheng, Z.-H., & Cai, Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3156 · Cited by 903 · cited 2×
“Parkinson’s disease mutations and α-synuclein oligomers can impair mitochondrial function or transport leading to an axonal energy deficit and synaptic loss.(81,107) Models of many Parkinson’s disease mutations including Pink1 and SNCA have reported impaired ATP production.”
BackgroundDopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., & Kaneko, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4029-08.2009 · Cited by 865
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853 · cited 1×
“DJ-1 is a ubiquitously-expressed multifunctional protein best known as a modulator of reactive oxygen species (ROS), protecting cells from oxidative stress through self-oxidation and initiating an anti-oxidant stress response.(97) Genetic deletions and point muta-”
BackgroundSun, F., Zeng, J., Jing, M., Zhou, J., Feng, J., Owen, S. F., Luo, Y., Li, F., Wang, H., Yamaguchi, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.042 · Cited by 837
LRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative Stress
Nguyen, H. N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R. E., Langston, W., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.01.013 · Cited by 745
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600 · cited 1×
“On the other hand, this death may be caused by programmed cell death following prolonged cellular dysfunction.(146) Whether or not neuronal death is the mechanism by which reduced DA release passes the threshold, ultimately it is the loss of DA content itself, rather than the death of neurons, which is re-”
BackgroundA Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598
Disruption of mitochondrial complex I induces progressive parkinsonism
González-Rodríguez, P., Zampese, E., Stout, K. A., Guzman, J. N., Ilijic, E., Yang, B., Tkatch, T., Stavarache, M. A., Wokosin, D. L., Gao, L., et al. (2021) · Nature · doi:10.1038/s41586-021-04059-0 · Cited by 546 · cited 2×
“demonstrated that early parkinsonism is caused by defective DA release by mitochondrial dysfunction preceding cell death.(143) In a conditional Ndufs2-knockout mouse that causes mitochondrial complex I disruption, loss of axonal DA release generated deficits in motor learning and fine motor control but was necessary b…”
BackgroundResultSchöndorf, D. C., Aureli, M., McAllister, F. E., Hindley, C. J., Mayer, F., Schmid, B., Sardi, S. P., Valsecchi, M., Hoffmann, S., Schwarz, L. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5028 · Cited by 543 · cited 3×
“Subchronic pharmacological inhibition of GCase causes nigrostriatal dopaminergic dysfunction in mice, producing a substantial evoked DA release deficit using in vivo microdialysis.68 Expression of the Parkinson’s disease-associated mutation GBA-L444P results in increased susceptibility to striatal DA deficits as measu…”
BackgroundImpaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient mice
Kitada, T., Pisani, A., Porter, D. R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P., Zhang, C., Pothos, E. N., & Shen, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702717104 · Cited by 540 · cited 1×
“Pink1 Pink1 KO mouse Decreased release None Not investigated Kitada et al.(64) Pink1 KO mouse Decreased release None Not investigated Zhi et al.”
BackgroundGoldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.041 · Cited by 538 · cited 3×
“ported decreased evoked release using FCV in DJ-1 knockout mice in the absence of neurodegeneration.(66) Importantly, this study re-”
BackgroundMethodResultMutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease
Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2349 · Cited by 536
Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., & Shen, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004676107 · Cited by 501 · cited 1×
“Striatal DA levels quantified by HPLC are also normal in Lrrk2 knockout mice.(90,91) Therefore, although LRRK2 plays a critical role in synaptic activity, a gain but not loss of function is detrimental to DA release.”
Axon degeneration in Parkinson's disease
Burke, R. E., & O'Malley, K. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 493 · cited 2×
“Brain imaging studies in humans in vivo suggest presynaptic defects precede symptom onset in Parkinson’s disease.(17,19,22,23) PET imaging of asymptomatic family members revealed presynaptic dopaminergic dysfunction, with reduced (18)F-DOPA uptake, a measure of pre-”
BackgroundVolles, M. J., & Lansbury, P. T. (2002) · Biochemistry · doi:10.1021/bi0121353 · Cited by 487
Mitochondrial dysfunction and mitophagy in parkinson’s disease: from mechanism to therapy
Malpartida, A. B., Williamson, M., Narendra, D. P., Wade-Martins, R., & Ryan, B. J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.007 · Cited by 482 · cited 1×
“Models of many Parkinson’s disease mutations including Pink1 and SNCA have reported impaired ATP production.(7,65,108,109) Defective mitochondria may also disrupt exocytosis through calcium dysregulation, as these organelles are critical for calcium buffering.”
BackgroundSelf-citationDefects in trafficking bridge Parkinson’s disease pathology and genetics
Abeliovich, A., & Gitler, A. D. (2016) · Nature · doi:10.1038/nature20414 · Cited by 462 · cited 1×
“Furthermore, intracellular and specifically axonal and vesicular trafficking is impaired in Parkinson’s disease with consequences to synaptic function.(117,118) Trafficking and or-”
BackgroundModeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437 · cited 1×
“centration used and aggregate subtype morphology obtained, as well as delivery strategies and injection sites, can lead to inconsistent results.(76,77) Nevertheless, these localized approaches have rap-”
BackgroundStriatal dopamine neurotransmission: Regulation of release and uptake
Sulzer, D., Cragg, S. J., & Rice, M. E. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.02.001 · Cited by 382 · cited 5×
“Mechanisms of defective DA release may not be limited to axonal dysfunction; modulation of DA release involves other neuronal and non-neuronal networks.(10) Recent research suggests these neuronal and non-neuronal striatal networks contribute to defective release in Parkinson’s disease.”
BackgroundInfluentialSelf-citationMechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
Bridi, J. C., & Hirth, F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00080 · Cited by 378
Autophagy in Parkinson's Disease
Hou, X., Watzlawik, J. O., Fiesel, F. C., & Springer, W. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.037 · Cited by 352 · cited 2×
“A major protein degradation pathway, autophagy, is critical to regulating protein turnover in neurons and has been connected to Parkinson’s disease-related mutations including SNCA, LRRK2, VPS35, parkin, Pink1 and DJ-1.(6,141)”
BackgroundPissadaki, E. K., & Bolam, J. P. (2013) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2013.00013 · Cited by 348 · cited 2×
“These factors are suggested to contribute to their preferential vulnerability to degeneration in Parkinson’s disease.(16) Early synaptic dysfunction in Parkinson’s disease has long been reported as a key feature in both Parkinson’s disease models and human patients.”
BackgroundModeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids
Kim, H., Park, H. J., Choi, H., Chang, Y., Park, H., Shin, J., Kim, J., Lengner, C. J., Lee, Y. K., & Kim, J. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.01.020 · Cited by 346
Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model
Janezic, S., Threlfell, S., Dodson, P. D., Dowie, M. J., Taylor, T. N., Potgieter, D., Parkkinen, L., Senior, S. L., Anwar, S., Ryan, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309143110 · Cited by 344 · cited 5×
“mouse model that expressed human α-synuclein at diseaserelevant levels, and which displayed age-dependent parkinsonian phenotypes, DA neurotransmission defects were observed.(51)”
BackgroundInfluentialSelf-citationLi, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., Elder, G. A., Rice, M. E., & Yue, Z. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5604-09.2010 · Cited by 341 · cited 1×
“G2019S BAC transgenic mouse Decreased release None None Li et al.(41) Human BAC G2019S mouse Decreased release None None Melrose et al.”
BackgroundImpaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 328 · cited 1×
“Synaptic dysfunction, or rather a side effect of it, might contribute to cell death through toxic cytosolic DA or α-synuclein accumulation.(115,145) On the other hand, this death may be caused by programmed cell death following prolonged cellular dysfunction.”
BackgroundSynaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease
Nguyen, M., Wong, Y. C., Ysselstein, D., Severino, A., & Krainc, D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.11.001 · Cited by 323 · cited 4×
“Both genetic deletion and overexpression of DAT decreases DA release through different mechanisms.113 Models of Parkinson’s disease with mutations in SNCA, Vps35, DJ-1, parkin and LRRK2 have reported alterations in DAT levels or function.46,50,129–131 Furthermore, tightly regulated endocytosis occurs immediately follo…”
BackgroundInfluentialR1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., & Shen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906334106 · Cited by 304
Piccini, P., Burn, D. J., Ceravolo, R., Maraganore, D., & Brooks, D. J. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199905)45:5<577::aid-ana5>3.0.co;2-o · Cited by 304 · cited 2×
“Of these twin pairs, several asymptomatic monozygotic cotwins with abnormal baseline scans later went on to develop clinical Parkinson’s disease.(26)”
BackgroundLarge α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N. K., & Shin, Y.-K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218424110 · Cited by 300 · cited 2×
“The addition of oligomeric α-synuclein and PFFs in the absence of genetic alterations results in DA release defects.(72,105) Further, many models of Parkinson’s disease-related proteins such as LRRK2, PINK1, GCase and VPS35 report increased α-synuclein expression and aggregation or decreased degradation(140)”
BackgroundAlpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation
Angelova, P. R., Choi, M. L., Berezhnov, A. V., Horrocks, M. H., Hughes, C. D., De, S., Rodrigues, M., Yapom, R., Little, D., Dolt, K. S., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0542-z · Cited by 296
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons
Lundblad, M., Decressac, M., Mattsson, B., & Björklund, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200575109 · Cited by 292
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease
Garcia-Reitböck, P., Anichtchik, O., Bellucci, A., Iovino, M., Ballini, C., Fineberg, E., Ghetti, B., Della Corte, L., Spano, P., Tofaris, G. K., et al. (2010) · Brain · doi:10.1093/brain/awq132 · Cited by 292 · cited 1×
“ity to aggregate exhibited KCl-evoked DA release defects using microdialysis.(70) These defects are not limited to animal models;”
BackgroundPolinski, N. K., Volpicelli-Daley, L. A., Sortwell, C. E., Luk, K. C., Cremades, N., Gottler, L. M., Froula, J., Duffy, M. F., Lee, V. M. Y., Martinez, T. N., et al. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171248 · Cited by 288 · cited 1×
“idly gained in popularity as a model to generate a progressive pathology useful to understand Parkinson’s disease in the context of dysfunction caused by α-synuclein aggregation, and efforts have been extended to standardize practices to reduce inconsistencies.(78) The α-synuclein PFF and oligomer treatment models hav…”
BackgroundProgressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
Yue, M., Hinkle, K. M., Davies, P., Trushina, E., Fiesel, F. C., Christenson, T. A., Schroeder, A. S., Zhang, L., Bowles, E., Behrouz, B., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.031 · Cited by 281 · cited 1×
“G2019S KI mouse Decreased release None None Yue et al.(43) Midbrain-specific (PitX3) overexpression of G2019S mouse Decreased release None None Liu et al.”
BackgroundThe Synaptic VesicleCycle Revisited
Südhof, T. C. (2000) · Neuron · doi:10.1016/s0896-6273(00)00109-4 · Cited by 276
Melrose, H. L., Dächsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., Kent, C. B., Korvatska, E., Taylor, J. P., Witten, L., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.010 · Cited by 275 · cited 1×
“Human BAC G2019S mouse Decreased release None None Melrose et al.(42) G2019S KI mouse Decreased release None None Yue et al.”
BackgroundArbuthnott, G. W., & Wickens, J. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2006.12.003 · Cited by 274 · cited 1×
“SNpc DANs have distinctive axonal arbours formed by extensive branching of long unmyelinated axons(14) that bear exceptionally large numbers of release sites (>10(5)).(15) Their propagation of action potentials has been proposed to pose extremely high energetic demands.”
BackgroundTang, F.-L., Erion, J. R., Tian, Y., Liu, W., Yin, D.-M., Ye, J., Tang, B., Mei, L., & Xiong, W.-C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0042-15.2015 · Cited by 269
Adams, J. R., van Netten, H., Schulzer, M., Mak, E., Mckenzie, J., Strongosky, A., Sossi, V., Ruth, T. J., Lee, C. S., Farrer, M., et al. (2005) · Brain · doi:10.1093/brain/awh607 · Cited by 262 · cited 1×
“Studies demonstrate that in asymptomatic Y1699C and R1441C leucine-rich repeat kinase 2 (LRRK2) mutation carriers, (18)F-DOPA uptake was normal, despite evidence for impaired DA function with abnormal DAT binding.(27,31) A longitudinal study that followed asymptomatic LRRK2 G2019S carriers who went on to convert to Pa…”
BackgroundJiang, H., Ren, Y., Yuen, E. Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G., Nakaso, K., Yan, Z., & Feng, J. (2012) · Nature Communications · doi:10.1038/ncomms1669 · Cited by 254 · cited 3×
“Parkin KO iPSC-derived DANs Increased release n/a n/a Jiang et al.(63) Pink1 Pink1 KO mouse Decreased release None Not investigated Kitada et al.”
BackgroundMeaningful silences: how dopamine listens to the ACh pause
Cragg, S. J. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.003 · Cited by 245
Self-citationHilker, R., Klein, C., Ghaemi, M., Kis, B., Strotmann, T., Ozelius, L. J., Lenz, O., Vieregge, P., Herholz, K., Heiss, W., et al. (2001) · Annals of Neurology · doi:10.1002/ana.74 · Cited by 243 · cited 3×
“monstrated that (18)F-DOPA uptake was reduced in asymptomatic carriers with a single parkin (PRKN) mutation allele when compared to a control cohort.(23,28) A 5-year follow-up study suggested that al-”
BackgroundResultUnregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice
Chen, L., Ding, Y., Cagniard, B., Van Laar, A. D., Mortimer, A., Chi, W., Hastings, T. G., Kang, U. J., & Zhuang, X. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3602-07.2008 · Cited by 239 · cited 1×
“Synaptic dysfunction, or rather a side effect of it, might contribute to cell death through toxic cytosolic DA or α-synuclein accumulation.(115,145) On the other hand, this death may be caused by programmed cell death following prolonged cellular dysfunction.”
BackgroundThakur, P., Breger, L. S., Lundblad, M., Wan, O. W., Mattsson, B., Luk, K. C., Lee, V. M. Y., Trojanowski, J. Q., & Björklund, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710442114 · Cited by 233
Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease
Dave, K. D., De Silva, S., Sheth, N. P., Ramboz, S., Beck, M. J., Quang, C., Switzer, R. C., Ahmad, S. O., Sunkin, S. M., Walker, D., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.009 · Cited by 222
Woodard, C. M., Campos, B. A., Kuo, S.-H., Nirenberg, M. J., Nestor, M. W., Zimmer, M., Mosharov, E. V., Sulzer, D., Zhou, H., Paull, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.023 · Cited by 222
LRRK2 links genetic and sporadic Parkinson's disease
Kluss, J. H., Mamais, A., & Cookson, M. R. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180462 · Cited by 221 · cited 2×
“Autosomal dominant gain-of-function mutations in LRRK2 result in the most common form of familial Parkinson’s disease.(87) LRRK2 en-”
BackgroundProts, I., Grosch, J., Brazdis, R.-M., Simmnacher, K., Veber, V., Havlicek, S., Hannappel, C., Krach, F., Krumbiegel, M., Schütz, O., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713129115 · Cited by 216 · cited 2×
“Parkinson’s disease mutations and α-synuclein oligomers can impair mitochondrial function or transport leading to an axonal energy deficit and synaptic loss.(81,107) Models of many Parkinson’s disease mutations including Pink1 and SNCA have reported impaired ATP production.”
BackgroundAn action potential initiation mechanism in distal axons for the control of dopamine release
Liu, C., Cai, X., Ritzau-Jost, A., Kramer, P. F., Li, Y., Khaliq, Z. M., Hallermann, S., & Kaeser, P. S. (2022) · Science · doi:10.1126/science.abn0532 · Cited by 213 · cited 1×
“Cholinergic interneurons strongly modify DA release and its dynamics,(147) which can occur locally by acting on the distal dopaminergic axon in the striatum.(148) Parkinson’s disease is sug-”
BackgroundChung, S. Y., Kishinevsky, S., Mazzulli, J. R., Graziotto, J., Mrejeru, A., Mosharov, E. V., Puspita, L., Valiulahi, P., Sulzer, D., Milner, T. A., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.012 · Cited by 205
Synaptic Vulnerability in Neurodegenerative Disease
Wishart, T. M., Parson, S. H., & Gillingwater, T. H. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000228202.35163.c4 · Cited by 204 · cited 1×
“This concept is not unique to Parkinson’s disease; impaired synaptic activity and function, referred to as synaptopathy, is observed in a wide variety of neurodegenerative diseases, including Huntington’s, Alzheimer’s and motor neuron disease.(18,20)”
BackgroundCalcium and Parkinson's disease
Surmeier, D. J., Schumacker, P. T., Guzman, J. D., Ilijic, E., Yang, B., & Zampese, E. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.168 · Cited by 202
Anwar, S., Peters, O., Millership, S., Ninkina, N., Doig, N., Connor-Robson, N., Threlfell, S., Kooner, G., Deacon, R. M., Bannerman, D. M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6194-10.2011 · Cited by 200 · cited 1×
“However, double knockout of both α and γ synuclein, and triple knockout of all three synucleins, α, β and γ (SynTKO) results in increased evoked striatal DA release ex vivo.(82,86) A recent study of α-synuclein knockout and SynTKO mice revealed a more complex role of α-synuclein on DA release using in vivo FCV, with r…”
BackgroundSelf-citationKhan, N. L., Valente, E. M., Bentivoglio, A. R., Wood, N. W., Albanese, A., Brooks, D. J., & Piccini, P. (2002) · Annals of Neurology · doi:10.1002/ana.10417 · Cited by 199
Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance
Heeman, B., Van den Haute, C., Aelvoet, S.-A., Valsecchi, F., Rodenburg, R. J., Reumers, V., Debyser, Z., Callewaert, G., Koopman, W. J. H., Willems, P. H. G. M., et al. (2011) · Journal of Cell Science · doi:10.1242/jcs.078303 · Cited by 198 · cited 6×
“Beyond supplying ATP and modulating Ca2+ levels, mitochondria are also key producers of ROS at the synaptic site.106 Models with Parkinson’s disease mutations such as Pink1, DJ-1 and SNCA have been connected to increased ROS.108,123 Further, cytosolic DA, which is increased in Parkinson’s disease models, undergoes aut…”
BackgroundInfluentialGerman, C. L., Baladi, M. G., McFadden, L. M., Hanson, G. R., & Fleckenstein, A. E. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010397 · Cited by 197 · cited 1×
“Alterations in SV pH or H-ATPase activity lead to ineffective VMAT2 activity and quantal size of DA release.(10,112) Disruption of this pH gradient might also occur through mitochondrial dysfunction as it requires ATP.”
BackgroundHinkle, K. M., Yue, M., Behrouz, B., Dächsel, J. C., Lincoln, S. J., Bowles, E. E., Beevers, J. E., Dugger, B., Winner, B., Prots, I., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-25 · Cited by 191 · cited 1×
“Studies of Lrrk2 knockout rats or mice report no decrease in basal or evoked DA release using microdialysis.(62,89) Striatal DA levels quantified by HPLC are also normal in Lrrk2 knockout mice.”
BackgroundLin, X., Parisiadou, L., Sgobio, C., Liu, G., Yu, J., Sun, L., Shim, H., Gu, X.-L., Luo, J., Long, C.-X., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1731-12.2012 · Cited by 189
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons
Bieri, G., Brahic, M., Bousset, L., Couthouis, J., Kramer, N. J., Ma, R., Nakayama, L., Monbureau, M., Defensor, E., Schüle, B., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01995-0 · Cited by 188
Papassotiropoulos, A., Bagli, M., Jessen, F., Bayer, T. A., Maier, W., Rao, M. L., & Heun, R. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199905)45:5<666::aid-ana18>3.0.co;2-3 · Cited by 186
Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184 · cited 2×
“In addition, an increase in extracellular DA concentration was detected using microdialysis in a transgenic mouse model overexpressing human wild-type α-synuclein under the Thy1 promoter, before a later change in striatal DA content and motor deficits, and without cell death.(54) Further, a mouse model expressing trun…”
Backgroundα-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration
Mosharov, E. V., Staal, R. G. W., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M. H., Troyer, M. D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0519-06.2006 · Cited by 165 · cited 1×
“Indeed, overexpression of SNCA mutation A30P leads to disrupted SV vesicle pH and an increase in cytosolic catecholamines.(116) Furthermore, intracellular and specifically axonal and vesicular trafficking is impaired in Parkinson’s disease with consequences to synaptic function.”
BackgroundSenior, S. L., Ninkina, N., Deacon, R., Bannerman, D., Buchman, V. L., Cragg, S. J., & Wade‐Martins, R. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06055.x · Cited by 164 · cited 2×
“atal DA release was reported in one knockout mouse model of α-synuclein,(84) other studies have reported no change to evoked striatal DA release levels.(82) However, double knockout of both α and γ synuclein, and triple knockout of all three synucleins, α, β and γ (SynTKO) results in increased evoked striatal DA relea…”
BackgroundSelf-citationGaugler, M. N. M., Genç, Ö., Bobela, W., Mohanna, S., Ardah, M. T., El‐Agnaf, O. M. A., Cantoni, M., Bensadoun, J., Schneggenburger, R., Knott, G. W., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0963-y · Cited by 163
Mechanisms and regulation of dopamine release
Liu, C., & Kaeser, P. S. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.01.001 · Cited by 161 · cited 3×
“Most of the studies discussed use either FCV or microdialysis coupled with HPLC-ECD.(8)”
BackgroundMethodInfluentialSynucleins Have Multiple Effects on Presynaptic Architecture
Vargas, K. J., Schrod, N., Davis, T., Fernandez-Busnadiego, R., Taguchi, Y. V., Laugks, U., Lucic, V., & Chandra, S. S. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.023 · Cited by 160
Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
Ghiglieri, V., Calabrese, V., & Calabresi, P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00295 · Cited by 159
Zambon, F., Cherubini, M., Fernandes, H. J. R., Lang, C., Ryan, B. J., Volpato, V., Bengoa-Vergniory, N., Vingill, S., Attar, M., Booth, H. D. E., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz038 · Cited by 154
Self-citationC9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation
Lall, D., Lorenzini, I., Mota, T. A., Bell, S., Mahan, T. E., Ulrich, J. D., Davtyan, H., Rexach, J. E., Muhammad, A. K. M. G., Shelest, O., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.020 · Cited by 147
Wersinger, C., Prou, D., Vernier, P., & Sidhu, A. (2003) · The FASEB Journal · doi:10.1096/fj.03-0152fje · Cited by 144
Keating, D. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04997.x · Cited by 141 · cited 5×
“Alterations in SV pH or H+-ATPase activity lead to ineffective VMAT2 activity and quantal size of DA release.10,112 Disruption of this pH gradient might also occur through mitochondrial dysfunction as it requires ATP.”
BackgroundInfluential“LRRK2: Autophagy and Lysosomal Activity”
Madureira, M., Connor-Robson, N., & Wade-Martins, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00498 · Cited by 137 · cited 2×
“A major protein degradation pathway, autophagy, is critical to regulating protein turnover in neurons and has been connected to Parkinson’s disease-related mutations including SNCA, LRRK2, VPS35, parkin, Pink1 and DJ-1.(6,141)”
BackgroundSelf-citationAndres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B. M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4357-09.2009 · Cited by 134
Munsie, L. N., Milnerwood, A. J., Seibler, P., Beccano-Kelly, D. A., Tatarnikov, I., Khinda, J., Volta, M., Kadgien, C., Cao, L. P., Tapia, L., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu582 · Cited by 134
Self-citationYun, S. P., Kim, D., Kim, S., Kim, S., Karuppagounder, S. S., Kwon, S.-H., Lee, S., Kam, T.-I., Lee, S., Ham, S., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0233-5 · Cited by 134 · cited 3×
“Subchronic pharmacological inhibition of GCase causes nigrostriatal dopaminergic dysfunction in mice, producing a substantial evoked DA release deficit using in vivo microdialysis.68 Expression of the Parkinson’s disease-associated mutation GBA-L444P results in increased susceptibility to striatal DA deficits as measu…”
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation
Khan, N. L., Scherfler, C., Graham, E., Bhatia, K. P., Quinn, N., Lees, A. J., Brooks, D. J., Wood, N. W., & Piccini, P. (2005) · Neurology · doi:10.1212/01.wnl.0000148725.48740.6d · Cited by 133 · cited 2×
“monstrated that (18)F-DOPA uptake was reduced in asymptomatic carriers with a single parkin (PRKN) mutation allele when compared to a control cohort.(23,28) A 5-year follow-up study suggested that al-”
ResultDOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function
Plotegher, N., Berti, G., Ferrari, E., Tessari, I., Zanetti, M., Lunelli, L., Greggio, E., Bisaglia, M., Veronesi, M., Girotto, S., et al. (2017) · Scientific Reports · doi:10.1038/srep40699 · Cited by 133
Postmortem studies in Parkinson's disease
Hartmann, A. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.3/ahartmann · Cited by 130 · cited 1×
“This is consistent with the understanding that Parkinson’s disease is not solely a movement disorder, with pathology not exclusively limited to dysfunction of motor control.(151)”
ResultGlucocerebrosidase Mutations in Parkinson Disease
O’Regan, G., deSouza, R.-M., Balestrino, R., & Schapira, A. H. (2017) · Journal of Parkinson's Disease · doi:10.3233/jpd-171092 · Cited by 127 · cited 2×
“While homozygous mutations in this gene result in the lysosomal storage disorder Gaucher’s disease, heterozygous mutations are connected to increased risk for Parkinson’s disease.(99) Exactly how GBA1 muta-”
BackgroundTozzi, A., Sciaccaluga, M., Loffredo, V., Megaro, A., Ledonne, A., Cardinale, A., Federici, M., Bellingacci, L., Paciotti, S., Ferrari, E., et al. (2021) · Brain · doi:10.1093/brain/awab242 · Cited by 127
Synaptic Vesicle Recycling Pathway Determines Neurotransmitter Content and Release Properties
Silm, K., Yang, J., Marcott, P. F., Asensio, C. S., Eriksen, J., Guthrie, D. A., Newman, A. H., Ford, C. P., & Edwards, R. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.031 · Cited by 126 · cited 3×
“Synaptic vesicle endocytosis, recycling and dopamine reuptake The ability to reconstitute the vesicular pool for subsequent release events is regulated by vesicle renewal and also reuptake, recycling and reloading of the neurotransmitter into SVs. Functioning as an electrogenic Na+/Cl− symporter, the DA transporter, D…”
BackgroundInfluentialPiccini, P., Morrish, P. K., Turjanski, N., Sawle, G. V., Burn, D. J., Weeks, R. A., Mark, M. H., Maraganore, D. M., Lees, A. J., & Brooks, D. J. (1997) · Annals of Neurology · doi:10.1002/ana.410410213 · Cited by 125 · cited 1×
“synaptic dopaminergic integrity or DA handling, in individuals who later went on to develop Parkinson’s disease.(24) (18)F-DOPA up-”
BackgroundImpaired dopamine release and synaptic plasticity in the striatum of Parkin−/− mice
Kitada, T., Pisani, A., Karouani, M., Haburcak, M., Martella, G., Tscherter, A., Platania, P., Wu, B., Pothos, E. N., & Shen, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06152.x · Cited by 125 · cited 1×
“Parkin KO mouse Decreased release Not investigated Not investigated Kitada et al.(60) Parkin KO mouse Decreased release None Present Goldberg et al.”
BackgroundMembrane transporters as mediators of synaptic dopamine dynamics: implications for disease
Lohr, K. M., Masoud, S. T., Salahpour, A., & Miller, G. W. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13357 · Cited by 124 · cited 1×
“overexpression of DAT decreases DA release through different mechanisms.(113) Models of Parkinson’s disease with mutations in SNCA, Vps35, DJ-1, parkin and LRRK2 have reported alterations in DAT levels or function.”
BackgroundGinns, E. I., Mak, S. K., Ko, N., Karlgren, J., Akbarian, S., Chou, V., Guo, Y., Lim, A., Samuelsson, S. J., LaMarca, M. L., et al. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.12.003 · Cited by 123
Parkin Increases Dopamine Uptake by Enhancing the Cell Surface Expression of Dopamine Transporter
Jiang, H., Jiang, Q., & Feng, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409282200 · Cited by 122
Reactive oxygen species regulate activity-dependent neuronal plasticity in Drosophila
Oswald, M. C. W., Brooks, P. S., Zwart, M., Mukherjee, A., West, R. J. H., Giachello, C. N., Morarach, K., Baines, R., Sweeney, S. T., & Landgraf, M. (2018) · eLife · doi:10.7554/elife.39393 · Cited by 121 · cited 1×
“ling has been identified as a key regulator of synaptic neurotransmission.(124) Overproduction of ROS inhibits SNARE-complex assembly and thus impairs exocytosis.”
BackgroundProgression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study
Nandhagopal, R., Mak, E., Schulzer, M., McKenzie, J., McCormick, S., Sossi, V., Ruth, T. J., Strongosky, A., Farrer, M. J., Wszolek, Z. K., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000335973.66333.58 · Cited by 120 · cited 2×
“Studies demonstrate that in asymptomatic Y1699C and R1441C leucine-rich repeat kinase 2 (LRRK2) mutation carriers, (18)F-DOPA uptake was normal, despite evidence for impaired DA function with abnormal DAT binding.(27,31) A longitudinal study that followed asymptomatic LRRK2 G2019S carriers who went on to convert to Pa…”
BackgroundResultSomatodendritic dopamine release: recent mechanistic insights
Rice, M. E., & Patel, J. C. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0185 · Cited by 120 · cited 1×
“In contrast to the conventional synapse, released DA is thought to act beyond individual synapses at extrasynaptic receptors on many cells and can also be released from the cell body and dendrites through somatodendritic release.(9) DA release is highly regu-”
BackgroundBelluzzi, E., Gonnelli, A., Cirnaru, M.-D., Marte, A., Plotegher, N., Russo, I., Civiero, L., Cogo, S., Carrion, M. P., Franchin, C., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0066-z · Cited by 119
Durante, V., de Iure, A., Loffredo, V., Vaikath, N., De Risi, M., Paciotti, S., Quiroga-Varela, A., Chiasserini, D., Mellone, M., Mazzocchetti, P., et al. (2019) · Brain · doi:10.1093/brain/awz065 · Cited by 116
Modeling α-Synuclein Propagation with Preformed Fibril Injections
Chung, H. K., Ho, H.-A., Pérez-Acuña, D., & Lee, S.-J. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.19046 · Cited by 116 · cited 1×
“centration used and aggregate subtype morphology obtained, as well as delivery strategies and injection sites, can lead to inconsistent results.(76,77) Nevertheless, these localized approaches have rap-”
BackgroundRinne, J. O., Laihinen, A., Ruottinen, H., Ruotsalainen, U., Någren, K., Lehikoinen, P., Oikonen, V., & Rinne, U. K. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00137-q · Cited by 114
Chandran, J. S., Lin, X. Z., Zapata, A. G., Höke, A., Shimoji, M., Moore, S. O., Galloway, M. P., Laird, F. M., Wong, P. C., Price, D. L., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.11.011 · Cited by 112 · cited 1×
“DJ-1 KO mouse None None Present Chandran et al.(67) Risk factor GBA Wild-type mice with chronic conduritol-β-epoxide treatment Decreased release Not investigated Present Ginns et al.”
BackgroundHolthoff, V. A., Vieregge, P., Kessler, J., Pietrzyk, U., Herholz, K., Bönner, J., Wagner, R., Wienhard, K., Pawlik, G., & Heiss, W. ‐. (1994) · Annals of Neurology · doi:10.1002/ana.410360209 · Cited by 109 · cited 1×
“take was also significantly reduced in non-manifesting twins that were discordant for Parkinson’s disease.(25,26) Of these twin pairs, several asymptomatic monozygotic cotwins with abnormal baseline scans later went on to develop clinical Parkinson’s disease.”
BackgroundVolta, M., Beccano-Kelly, D. A., Paschall, S. A., Cataldi, S., MacIsaac, S. E., Kuhlmann, N., Kadgien, C. A., Tatarnikov, I., Fox, J., Khinda, J., et al. (2017) · eLife · doi:10.7554/elife.28377 · Cited by 108 · cited 2×
“G2019S KI mouse Increased release Not investigated Not investigated Volta et al.(46) iPSC-derived DANs with I2020T Decreased release n/a n/a Ohta et al.”
BackgroundSelf-citationGenetics of Parkinson’s disease and related disorders
Zhang, P.-L., Chen, Y., Zhang, C.-H., Wang, Y., & Fernández-Fúnez, P. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105047 · Cited by 103 · cited 1×
“Although ∼10% of Parkinson’s disease cases can be linked to inherited monogenic mutations, collectively referred to as familial Parkinson’s disease, most cases, which are referred to as idiopathic or sporadic, have undetermined origin.(1) The subpopulation of dopamine (DA)-producing neurons of the sub-”
BackgroundYavich, L., Oksman, M., Tanila, H., Kerokoski, P., Hiltunen, M., van Groen, T., Puoliväli, J., Männistö, P. T., García-Horsman, A., MacDonald, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.010 · Cited by 100 · cited 2×
“Human A30P mouse Decreased release None Present Yavich et al.(58) Autosomal recessive Parkin Parkin KO mouse Decreased release None None Oyama et al.”
BackgroundResultAlpha-synuclein modulates dopamine neurotransmission
Butler, B., Sambo, D. O., & Khoshbouei, H. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.06.001 · Cited by 98
Longo, F., Mercatelli, D., Novello, S., Arcuri, L., Brugnoli, A., Vincenzi, F., Russo, I., Berti, G., Mabrouk, O. S., Kennedy, R. T., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0426-8 · Cited by 97
Xiong, Y., Neifert, S., Karuppagounder, S. S., Liu, Q., Stankowski, J. N., Lee, B. D., Ko, H. S., Lee, Y., Grima, J. C., Mao, X., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712648115 · Cited by 97
Neuroimaging in pre-motor Parkinson's disease
Barber, T. R., Klein, J. C., Mackay, C. E., & Hu, M. T. M. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.04.011 · Cited by 84
Motor learning and metaplasticity in striatal neurons: relevance for Parkinson’s disease
Giordano, N., Iemolo, A., Mancini, M., Cacace, F., De Risi, M., Latagliata, E. C., Ghiglieri, V., Bellenchi, G. C., Puglisi-Allegra, S., Calabresi, P., et al. (2018) · Brain · doi:10.1093/brain/awx351 · Cited by 81
Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice
Cataldi, S., Follett, J., Fox, J. D., Tatarnikov, I., Kadgien, C., Gustavsson, E. K., Khinda, J., Milnerwood, A. J., & Farrer, M. J. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0063-3 · Cited by 77 · cited 7×
“A further Vps35-D630N knock-in mouse model was reported to have an early (at 3 months) increase in evoked DA release by FCV.(50) Table 1 Dopamine release defects in Parkinson’s disease models”
BackgroundInfluentialSloan, M., Alegre-Abarrategui, J., Potgieter, D., Kaufmann, A.-K., Exley, R., Deltheil, T., Threlfell, S., Connor-Robson, N., Brimblecombe, K., Wallings, R., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv628 · Cited by 73 · cited 3×
“onstrate specificity of release deficits in rodent models not only to DANs, but also regionally to the dorsal, but not ventral, striatum.(40,51,57) Understanding the preferential vulnerability of specific networks to dysfunction in Parkinson’s disease while others re-”
BackgroundResultSelf-citationCondon, M. D., Platt, N. J., Zhang, Y.-F., Roberts, B. M., Clements, M. A., Vietti-Michelina, S., Tseu, M.-Y., Brimblecombe, K. R., Threlfell, S., Mann, E. O., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12264-9 · Cited by 72 · cited 1×
“tial propagation, DA release probability and its dynamics during activity.(10,13) DA acts through D1- or D2-type receptors on recipient cells that probably include all striatal cells.”
BackgroundSelf-citationOhta, E., Nihira, T., Uchino, A., Imaizumi, Y., Okada, Y., Akamatsu, W., Takahashi, K., Hayakawa, H., Nagai, M., Ohyama, M., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv212 · Cited by 70 · cited 1×
“iPSC-derived DANs with I2020T Decreased release n/a n/a Ohta et al.(47) iPSC-derived DANs with I723V and M23497T Decreased release n/a n/a Luo et al.”
BackgroundSomayaji, M., Cataldi, S., Choi, S. J., Edwards, R. H., Mosharov, E. V., & Sulzer, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013652117 · Cited by 70 · cited 1×
“A recent study of α-synuclein knockout and SynTKO mice revealed a more complex role of α-synuclein on DA release using in vivo FCV, with roles in facilitation and depression of DA release dependent on specific patterns of neuronal activity.(85)”
BackgroundImpaired striatal dopamine release in homozygous Vps35 D620N knock-in mice
Ishizu, N., Yui, D., Hebisawa, A., Aizawa, H., Cui, W., Fujita, Y., Hashimoto, K., Ajioka, I., Mizusawa, H., Yokota, T., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw279 · Cited by 68 · cited 2×
“VPS35 D620N KI mouse Decreased release None None Ishizu et al.(49) D620N KI mouse Increased release None None Cataldi et al.”
BackgroundSidlauskaite, E., Gibson, J. W., Megson, I. L., Whitfield, P. D., Tovmasyan, A., Batinic-Haberle, I., Murphy, M. P., Moult, P. R., & Cobley, J. N. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.012 · Cited by 68 · cited 1×
“Indeed, overproduction of mitochondrial ROS induced motor defects by impaired synaptic activity in motor neurons in Xenopus laevis tadpoles.(125) Damage to the SV pool can also occur in other ways.”
BackgroundLiu, G., Sgobio, C., Gu, X., Sun, L., Lin, X. Z., Yu, J. H., Parisiadou, L., Xie, C., Sastry, N. G., Ding, J., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv249 · Cited by 66 · cited 5×
“TH, the rate-limiting enzyme in DA synthesis, has been shown to have decreased protein levels or decreased activity in models of Parkinson’s disease carrying mutations in LRRK2, SNCA, DJ-1 and PINK1.”
BackgroundInfluentialLRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25
Yun, H. J., Park, J., Ho, D. H., Kim, H., Kim, C.-H., Oh, H., Ga, I., Seo, H., Chang, S., Son, I., et al. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.68 · Cited by 64 · cited 1×
“phorylation of Snapin inhibits SNAP25 and results in the loss of readily releasable pool, impairing exocytosis.(102) Further, the addition of α-synuclein oligomers inhibits SNARE-complex formation by binding SNARE protein, synaptobrevin-2.”
BackgroundRoberts, B. M., Doig, N. M., Brimblecombe, K. R., Lopes, E. F., Siddorn, R. E., Threlfell, S., Connor-Robson, N., Bengoa-Vergniory, N., Pasternack, N., Wade-Martins, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18247-5 · Cited by 63 · cited 4×
“ease model with human SNCA overexpression, leading to enhanced GABAergic inhibition of DA release that will support DA release deficits.(142) Thus, other networks operating at the level of DA axons might contribute to, or conversely partly mask, defective DA release in Parkinson’s disease.”
BackgroundInfluentialSelf-citationVPS35 Parkinson’s disease phenotype resembles the sporadic disease
The Austrian VPS-35 Investigators Team, Struhal, W., Presslauer, S., Spielberger, S., Zimprich, A. A., Auff, E., Bruecke, T., Poewe, W. H., & Ransmayr, G. N. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1179-1 · Cited by 60 · cited 1×
“Parkinson’s disease clinically indistinguishable from idiopathic Parkinson’s disease.(94)”
BackgroundPositron emission tomography in premotor Parkinson's disease
Stoessl, A. J. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70041-5 · Cited by 58 · cited 2×
“Brain imaging studies in humans in vivo suggest presynaptic defects precede symptom onset in Parkinson’s disease.(17,19,22,23) PET imaging of asymptomatic family members revealed presynaptic dopaminergic dysfunction, with reduced (18)F-DOPA uptake, a measure of pre-”
BackgroundMolecular and functional architecture of striatal dopamine release sites
Banerjee, A., Imig, C., Balakrishnan, K., Kershberg, L., Lipstein, N., Uronen, R.-L., Wang, J., Cai, X., Benseler, F., Rhee, J. S., et al. (2022) · Neuron · doi:10.1016/j.neuron.2021.10.028 · Cited by 58
Taylor, T. N., Potgieter, D., Anwar, S., Senior, S. L., Janezic, S., Threlfell, S., Ryan, B., Parkkinen, L., Deltheil, T., Cioroch, M., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.005 · Cited by 55 · cited 2×
“onstrate specificity of release deficits in rodent models not only to DANs, but also regionally to the dorsal, but not ventral, striatum.(40,51,57) Understanding the preferential vulnerability of specific networks to dysfunction in Parkinson’s disease while others re-”
BackgroundSelf-citationLoss of nigral excitation of cholinergic interneurons contributes to parkinsonian motor impairments
Cai, Y., Nielsen, B. E., Boxer, E. E., Aoto, J. N., & Ford, C. (2021) · Neuron · doi:10.1016/j.neuron.2021.01.028 · Cited by 55 · cited 1×
“eral striatum and a downregulation of glutamate mGluR1 receptors in striatal cholinergic interneurons where, remarkably, targeted reexpression of these receptors can rescue motor deficits.(150)”
Impaired in vivo dopamine release in parkin knockout mice
Oyama, G., Yoshimi, K., Natori, S., Chikaoka, Y., Ren, Y., Funayama, M., Shimo, Y., Takahashi, R., Nakazato, T., Kitazawa, S., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.065 · Cited by 54 · cited 2×
“Homozygous parkin knockout mice have decreased evoked DA release between 2 and 6 months of age using in vivo voltammetry(59) and ex vivo single-pulse amperometry,(60) but interestingly, no difference at 9 and 12 months.(59) In contrast, increased basal DA release was reported using in vivo microdialysis at later ages…”
BackgroundMolecular Mechanisms for the Coupling of Endocytosis to Exocytosis in Neurons
Xie, Z.-L., Long, J., Liu, J., Chai, Z., Kang, X., & Wang, C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00047 · Cited by 54 · cited 1×
“Furthermore, tightly regulated endocytosis occurs immediately following exocytosis to retrieve the SV membrane and machinery for further neurotransmission.(132)”
BackgroundIntracellular soluble α‐synuclein oligomers reduce pyramidal cell excitability
Kaufmann, T. J., Harrison, P. M., Richardson, M. J. E., Pinheiro, T. J. T., & Wall, M. J. (2016) · The Journal of Physiology · doi:10.1113/jp271968 · Cited by 53 · cited 1×
“Protofibrillar α-synuclein and oligomers disrupt the SV membrane allowing DA to spill out into the cytosol(126) and alter neuron excitability.(127)”
BackgroundAre genetic and idiopathic forms of Parkinson's disease the same disease?
Guedes, L. C., Mestre, T., Outeiro, T. F., & Ferreira, J. J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14902 · Cited by 53
VPS35 regulates cell surface recycling and signaling of dopamine receptor D1
Wang, C., Niu, M., Zhou, Z., Zheng, X., Zhang, L., Tian, Y., Yu, X., Bu, G., Xu, H., Ma, Q., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.05.016 · Cited by 52
Pavese, N., Khan, N. L., Scherfler, C., Cohen, L., Brooks, D. J., Wood, N. W., Bhatia, K. P., Quinn, N. P., Lees, A. J., & Piccini, P. P. (2009) · Movement Disorders · doi:10.1002/mds.22817 · Cited by 51 · cited 1×
“ger and longer-term longitudinal follow-up study, would be required.(29) Asymptomatic individuals heterozygous for PTEN-induced kinase 1 (PINK1) mutations also demonstrated a sig-”
BackgroundLimanaqi, F., Biagioni, F., Gambardella, S., Ryskalin, L., & Fornai, F. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00299 · Cited by 51 · cited 3×
“Reports have suggested protein turnover machinery may get ‘clogged’ in Parkinson’s disease, thus leading to accumulation of many different proteins and disruption of synaptic homeostasis.(118) Indeed, altered synaptic protein homeostasis and defective protein turnover is a consistent feature of many Parkinson’s diseas…”
BackgroundDJ-1 deficiency impairs synaptic vesicle endocytosis and reavailability at nerve terminals
Kyung, J. W., Kim, J.-M., Lee, W., Ha, T.-Y., Cha, S.-H., Chung, K.-H., Choi, D.-J., Jou, I., Song, W. K., Joe, E.-H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708754115 · Cited by 50 · cited 1×
“Further to this list, both complete DJ-1 knockout as well as Parkinson’s disease-related DJ-1 mutations disrupt SV endocytosis.(136) Substantial evidence supports that defect-”
BackgroundSanchez, G. M., Varaschin, R. K., Büeler, H., Marcogliese, P. C., Park, D. S., & Trudeau, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094826 · Cited by 48 · cited 12×
“Knockout of Pink1 results in an age-dependent decrease in evoked DA release using FCV ex vivo with no effect at 3–4 months but a 30% decrease at ∼12 months of age in the absence of neurodegeneration.65 Decreased evoked DA release at early ages has been reported in some models using amperometry ex vivo,64 but not in ot…”
BackgroundMethodResultInfluentialLoss of PINK1 causes age-dependent decrease of dopamine release and mitochondrial dysfunction
Zhi, L., Qin, Q., Muqeem, T., Seifert, E. L., Liu, W., Zheng, S., Li, C., & Zhang, H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.025 · Cited by 47
Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease
Sierra, M., Martínez‐Rodríguez, I., Sánchez‐Juan, P., Aramburu, I. G., Jiménez-Alonso, M., Sánchez‐Rodríguez, A., Berciano, J., Banzo, I., & Infante, J. (2017) · Neurology · doi:10.1212/wnl.0000000000004185 · Cited by 45 · cited 1×
“A longitudinal study that followed asymptomatic LRRK2 G2019S carriers who went on to convert to Parkinson’s disease by the time of a 4-year reevaluation revealed a lower striatal DAT binding at baseline than nonconverters.(32) Brain imaging of patients with prodromal Parkinson’s disease, including hyposmic and REM sle…”
BackgroundBasal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum
Creed, R. B., Menalled, L., Casey, B., Dave, K. D., Janssens, H. B., Veinbergs, I., van der Hart, M., Rassoulpour, A., & Goldberg, M. S. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.04.033 · Cited by 41
Rab GTPases as Physiological Substrates of LRRK2 Kinase
Seol, W., Nam, D., & Son, I. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.2.134 · Cited by 41 · cited 1×
“A well-characterized mechanism for the involvement of LRRK2 in defective neurotransmission is by the role it plays in the phosphorylation of RABs, such as Rab5b, key players in SV endocytosis and trafficking.(133) LRRK2 can also regulate endocytosis and SV recycling through phosphorylation of auxilin, endophilinA and…”
BackgroundLin, M., Mackie, P. M., Shaerzadeh, F., Gamble‐George, J., Miller, D. R., Martyniuk, C. J., & Khoshbouei, H. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01203-9 · Cited by 40
Impaired Neurotransmitter Release in Alzheimer’s and Parkinson’s Diseases
Shen, J. (2010) · Neurodegenerative Diseases · doi:10.1159/000285511 · Cited by 38 · cited 2×
“This concept is not unique to Parkinson’s disease; impaired synaptic activity and function, referred to as synaptopathy, is observed in a wide variety of neurodegenerative diseases, including Huntington’s, Alzheimer’s and motor neuron disease.(18,20)”
BackgroundStriatal Dopamine Transmission Is Subtly Modified in Human A53Tα-Synuclein Overexpressing Mice
Platt, N. J., Gispert, S., Auburger, G. W. J., & Cragg, S. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036397 · Cited by 35
Self-citationCresto, N., Gaillard, M., Gardier, C., Gubinelli, F., Diguet, E., Bellet, D., Legroux, L., Mitja, J., Aurégan, G., Guillermier, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104614 · Cited by 27
Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells
Ishikawa, S., Tanaka, Y., Takahashi-Niki, K., Niki, T., Ariga, H., & Iguchi‐Ariga, S. M. M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.095 · Cited by 26 · cited 3×
“Parkinson’s disease models with mutations in LRRK2, DJ-1 or VPS35 have alterations in VMAT2 levels, pointing towards disturbances in SV loading.(45,50,111) SV loading depends on an electro-”
BackgroundModeling α-Synuclein Propagation with Preformed Fibril Injections
Chung, H. K., Ho, H.-A., Pérez-Acuña, D., & Lee, S. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.19046.e · Cited by 25
Sun, F., Salinas, A. G., Filser, S., Blumenstock, S., Medina-Luque, J., Herms, J. W., & Sgobio, C. (2021) · Brain Pathology · doi:10.1111/bpa.13036 · Cited by 23 · cited 1×
“The addition of oligomeric α-synuclein and PFFs in the absence of genetic alterations results in DA release defects.(72,105) Further, many models of Parkinson’s disease-related proteins such as LRRK2, PINK1, GCase and VPS35 report increased α-synuclein expression and aggregation or decreased degradation(140)”
BackgroundLuk, B., Mohammed, M., Liu, F., & Lee, F. J. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136641 · Cited by 22
Luo, F., Luo, S., Qian, W., Zhang, L., Chen, C., Xu, M., Wang, G., Wang, Z., Wang, J., & Wang, W. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102027 · Cited by 10
Pink1 Regulates Tyrosine Hydroxylase Expression and Dopamine Synthesis
Lu, L., Jia, H., Gao, G., Duan, C., Ren, J., Li, Y., & Yang, H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170832 · Cited by 7 · cited 2×
“TH, the rate-limiting enzyme in DA synthesis, has been shown to have decreased protein levels or decreased activity in models of Parkinson’s disease carrying mutations in LRRK2, SNCA, DJ-1 and PINK1.”
Background
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 141
“Corresponding to dopamine depletion, severalpathologicalprocesses that regulate dopamine synthesis occur in the brain 254 .”
BackgroundThe gut microbiota–brain axis in neurological disorders
You, M., Chen, N., Yang, Y., Cheng, L., He, H., Cai, Y., Liu, Y., Liu, H., & Hong, G. (2024) · MedComm · doi:10.1002/mco2.656 · Cited by 132
“155,194 It has been reported that GI disorders and gut dysbiosis occur before the onset of motor symptoms in PD. 195 Aggregation of α - Synuclein ( α Syn) is a characteristic protein in PD, which usually leads to motor dysfunction.”
BackgroundInfluentialLevodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Riederer, P. F., Strobel, S., Nagatsu, T., Watanabe, H., Chen, X. M., Löschmann, P. A., Sian‐Hülsmann, J., Jost, W. H., Müller, T., Dijkstra, J. M., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02893-4 · Cited by 125
“This is probably due to the inability of the compensation mechanisms to overcome the progressive cellular dysfunction (Cramb et al. 2023).”
Liu, Y., Zhang, Y., Wang, C., Zeng, X., Lei, J., Hou, J., Huo, D., & Hou, C. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c06213 · Cited by 69
Metadata
- Authors
- Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R.
- Affiliations
- University of Oxford (GB)
- Oxford Parkinson’s Disease Centre and Department of Physiology, Anatomy and Genetics, University of Oxford , Oxford, OX1 3QU , UK
- Corresponding author
- Cragg, Stephanie J
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-02
- Volume
- 146
- Issue
- 8
- Pages
- 3117-3132
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10393405
- OpenAlex
- W4323036321
- Cited by
- 207
- References
- 157
- Citations by year
- 2026: 63 · 2025: 75 · 2024: 60 · 2023: 8
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Monument Trust Discovery Award from Parkinson’s UK (J-1403)
- MJFF (ASAP-020370)
- Natural Sciences and Engineering Research Council of Canada (PGSD3-517039-2018)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- Parkinson's disease, dopamine release, dopaminergic neurons, striatal dopamine, neurodegeneration, Parkinson's disease model, pathophysiology
- MeSH terms
- Dopamine, Humans, Parkinson Disease, Neurodegenerative Diseases, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.